Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Issue 5 (16th April 2019) - Mascarenhas, John; Baer, Maria R.; Kessler, Craig; Hexner, Elizabeth; Tremblay, Douglas; Price, Leah; Sandy, Lonette; Weinberg, Rona; Pahl, Heike; Silverman, Lewis R.; Goldberg, Judith D.; Kosiorek, Heidi; et al.